Logo

Gen InCode: Bill Rhodes

Jan 08, 2021

Gen InCode, a privately owned UK-based company specializing in cardiovascular disease genetic risk assessment, has appointed Bill Rhodes as non-executive chairman. Rhodes has previously served as worldwide president of Becton Dickinson's Biosciences business and was BD's corporate executive officer for strategy and corporate development. Rhodes also currently serves as chairman at OpGen, Omega Diagnostics Group, and CytoSmart Technologies. He was formerly chairman of the Curetis supervisory board until that company's merger with OpGen.

Breaking News
The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.